spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  paliperidone 

 HSMN NewsFeed - 24 Jan 2020
ANI Announces Launch of Tolterodine Extended-Release Capsules
Biopharmaceuticals Urology Generics Product Launch
 HSMN NewsFeed - 14 Jan 2020
ANI Announces Launch of Paliperidone Extended-Release Tablets
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 29 Nov 2013
New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
Biopharmaceuticals
 HSMN NewsFeed - 6 Feb 2009
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2008
Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 29 Oct 2007
Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2007
INVEGA(R) Receives Positive Opinion From European Committee for Human Medicinal Products for Treatment of Schizophrenia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Biopharmaceuticals
 HSMN NewsFeed - 20 Dec 2006
INVEGA(TM) Approved By FDA as New Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Nov 2006
Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release tablets as Brand Name for Its Investigational Atypical Antipsychotic
Biopharmaceuticals
 HSMN NewsFeed - 29 Sep 2006
FDA Issues Approvable Letter for Paliperidone ER for the Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 May 2006
Clinical Study of Investigational Drug Paliperidone ER Demonstrated Efficacy and Tolerability in the Treatment of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 5 May 2006
Janssen-Cilag Submits Marketing Authorization Application in Europe for New Treatment for Schizophrenia
Biopharmaceuticals Drug Delivery
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
paliperidone
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.